Companies · Biotechnology

Nu-Tek BioSciences, LLC

MINNETONKA · Biotechnology

Diligence memoA one-page analyst read on Nu-Tek BioSciences, LLC — recommendation, valuation, rhythm, risks.→
$1.7M
Total raised · real
1
Rounds
—
Latest step-up
Top 76%
Sector rank · raised
Seed
Latest stage · inferred · Thu May 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Nu-Tek BioSciences, LLC looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.09× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
  • Within the normal band (109% of peer median) for its niche.
Dormant
  • Last raise 3.2 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Nu-Tek BioSciences, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
3.4 yr record
Peak capital year was 2023 with $1.7M across 1 filings.
Market position
ahead of 25% of Biotechnology peers
Capital scale is ahead of 25% of Biotechnology peers; modeled value is above 25% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2023: $1.7M across 1 filings.
  • Largest single filing was $1.7M on 2023-05-04.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Nu-Tek BioSciences, LLC is one of 4293 Biotechnology companies tracked from MINNETONKA. By capital raised it ranks in the long tail (ahead of 25% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
8
Investors (latest)
2023-05-04
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$5.0M$10M$15M$20MSeed · 2023-05-04 Raised $1.7M (real) Modeled valuation $15M (est)$1.7M$15MSeed2023

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.7M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$15.5M
Base estimate est.
$1.2M
Conservative case
$56.4M
Upside case
$8.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
3.2 yr
Elapsed time used
3.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
3.4 yr
On record since
2023
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▼ 0.2× of median
This company$1.7M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage)▼ 1.0× of median
This company$1.7M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages)▼ 0.2× of median
This company$15.5M
Sector median$64.2M

Raised more than 25% of sector peers (real $). Modeled value above 25% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #95 of 207.

This companyCohort peer
$10.0M$100.0M$1.0M$10.0MCapital raised (log)Mesentech Inc. · Seed Raised $3.9M · modeled $65.7M (est)Marlinspike Therapeutics, Inc. · Seed Raised $3.5M · modeled $64.4M (est)Microbial Machines, Inc. · Seed Raised $3.9M · modeled $63.7M (est)Pearl Diagnostics, Inc. · Seed Raised $3.5M · modeled $62.9M (est)Crossfire Medical Inc · Seed Raised $3.0M · modeled $57.5M (est)Design Pharmaceuticals, Inc. · Seed Raised $3.0M · modeled $57.0M (est)Tekv Holdings LLC · Seed Raised $4.0M · modeled $55.5M (est)Mi-Helper, Inc. · Seed Raised $4.0M · modeled $50.9M (est)Thelium Therapeutics Inc. · Seed Raised $3.1M · modeled $50.7M (est)Turtle Health, Inc. · Seed Raised $2.7M · modeled $49.1M (est)Accufix Holdings, Inc. · Seed Raised $4.2M · modeled $46.7M (est)Kyttaro Ltd · Seed Raised $5.2M · modeled $45.5M (est)Nu-Tek BioSciences, LLC (this company) Raised $1.7M · modeled $15.5M (est)Nu-Tek BioSciences, LLC
CompanyStageRaised · realValue · estvs peer med.
Mesentech Inc.Seed$3.9M$65.7M4.61×
Marlinspike Therapeutics, Inc.Seed$3.5M$64.4M4.52×
Microbial Machines, Inc.Seed$3.9M$63.7M4.47×
Pearl Diagnostics, Inc.Seed$3.5M$62.9M4.41×
Crossfire Medical IncSeed$3.0M$57.5M4.04×
Design Pharmaceuticals, Inc.Seed$3.0M$57.0M4.00×
Tekv Holdings LLCSeed$4.0M$55.5M3.89×
Mi-Helper, Inc.Seed$4.0M$50.9M3.58×
Thelium Therapeutics Inc.Seed$3.1M$50.7M3.56×
Turtle Health, Inc.Seed$2.7M$49.1M3.45×
Accufix Holdings, Inc.Seed$4.2M$46.7M3.28×
Kyttaro LtdSeed$5.2M$45.5M3.20×
Nu-Tek BioSciences, LLC this companySeed$1.7M$15.5M1.09×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.7M2023-05-04$8.4M$15.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.7M2023-05-04
    • First recorded raise — entered as Seed.
    • 8 investors on this round.
Intelligence
—
Modeled next raise
$2.7M
Modeled next size est.range $1.7M–$4.3M
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Kent McCoy——2023-05
Thomas L. Yezzi——2023-05
Registry & provenance

Nu-Tek BioSciences, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1982335
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Avantia Labs Inc.BiotechnologySeed$1.7M$11.8Msame sector · same stage
Serene Oncology, LLCBiotechnologySeed$1.8M$12.0Msame sector · same stage
Kaida BioPharma Inc.BiotechnologySeed$1.6M$11.1Msame sector · same stage
Sensible Biotechnologies, Inc.BiotechnologySeed$1.8M$19.2Msame sector · same stage
Immunologix, Inc.BiotechnologySeed$1.5M$11.1Msame sector · same stage
Hillhurst Biopharmaceuticals, Inc.BiotechnologySeed$1.8M$13.9Msame sector · same stage
Amplfied Sciences, Inc.BiotechnologySeed$1.5M$15.2Msame sector · same stage
PhenoBiome, Inc.BiotechnologySeed$1.5M$18.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
NuShores Biosciences LLCBiotechnologySeed$64.4M90%
Nu-Med Plus, Inc.BiotechnologyPre-Seed$36.5M90%
Tekv Holdings LLCBiotechnologySeed$55.5M90%
NuVera Medical, Inc.BiotechnologySeries A$423.0M88%
NantBio, Inc.BiotechnologySeries C$856.7M88%
Taiga Biotechnologies, Inc.BiotechnologySeries A$485.3M88%
NuProbe GlobalBiotechnologySeries C$847.0M88%
Tetragenetics IncBiotechnologySeed$39.9M87%
Frequently asked
How much funding has Nu-Tek BioSciences, LLC raised?
Nu-Tek BioSciences, LLC has raised approximately $1.7M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Nu-Tek BioSciences, LLC's estimated valuation?
Provath's modeled valuation for Nu-Tek BioSciences, LLC is approximately $15.5M (modeled range $1.2M–$56.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Nu-Tek BioSciences, LLC at?
Nu-Tek BioSciences, LLC's latest modeled financing stage is Seed. Its most recent recorded round closed around Thu May 04.
What does Nu-Tek BioSciences, LLC do and where is it based?
Nu-Tek BioSciences, LLC operates in the Biotechnology sector, based in MINNETONKA.
Explore related

See where Nu-Tek BioSciences, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Nu-Tek BioSciences, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.